Join the club for FREE to access the whole archive and other member benefits.

Juvenescence

Developing therapies against different aging related diseases.

Juvenescence is a bio-pharma development company developing therapies focused on allowing people worldwide to live longer, healthier lives. We have raised USD $65M to build an ecosystem and pipeline of assets targeting ageing, age-related disease and regeneration.

Visit website: https://www.juvenescence.ltd/

Juvenescence is also referenced in the following:

Company

Developing preventative medicines for age-related disease using ketone bodies

Company

Focused on a novel target linked to one of the fundamental processes of aging

People at Juvenescence

Company Representative

CEO at Juvenescence and chairman of Portage Biotech, Inc.

Academic

Chief Executive Officer of the Epigenetics Division of Juvenescence Limited

Juvenescence News

Labiotech gathers feedback from European biotechs on Unity failure

Labiotech - 28-Aug-2020

General feeling that failures are bound to happen - but that their approaches can succeed

Read more...

Juvenescence appoints a new CEO for its Epigenetic Division and Souvien Bio Ltd

Juvenescence - 11-Jun-2020

Goal is to develop drugs that target epigenetic mechanisms associated with neurodegeneration

Read more...

Orion College ageing research receives 1 million UK pounds from Jim Mellon

Life Extension Advocacy Foundation (LEAF) - 18-May-2020

He believes in the importance of boosting immunoresilience among elderly

Read more...

Master Investor Magazine focuses on longevity in its Autumn edition

Master Investor - 01-Nov-2019

Interesting articles and some useful investment opportunities

Read more...

A mission to change the lives of 1 billion people

Telegraph - 23-Sep-2019

Life extension technology will be expensive, so it'll create inequalities between poor, rich people

Read more...

Today's 50 year-olds may live another 100 years

Forbes - 26-Aug-2019

Good summary of some major investments in life extension companies

Read more...